Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Change in Accured Expenses: 2021-2025

Historic Change in Accured Expenses for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$1.1 million.

  • Prime Medicine's Change in Accured Expenses fell 118.06% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 164.53%. This contributed to the annual value of $1.8 million for FY2024, which is 4.84% up from last year.
  • Latest data reveals that Prime Medicine reported Change in Accured Expenses of -$1.1 million as of Q3 2025, which was down 121.55% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Change in Accured Expenses registered a high of $33.3 million during Q4 2021, and its lowest value of -$33.3 million during Q1 2022.
  • Over the past 3 years, Prime Medicine's median Change in Accured Expenses value was $536,000 (recorded in 2024), while the average stood at $76,455.
  • The largest annual percentage gain for Prime Medicine's Change in Accured Expenses in the last 5 years was 826.31% (2025), contrasted with its biggest fall of 118.06% (2025).
  • Prime Medicine's Change in Accured Expenses (Quarterly) stood at $33.3 million in 2021, then slumped by 87.73% to $4.1 million in 2022, then tumbled by 38.53% to $2.5 million in 2023, then slumped by 105.73% to -$144,000 in 2024, then plummeted by 118.06% to -$1.1 million in 2025.
  • Its Change in Accured Expenses stands at -$1.1 million for Q3 2025, versus $5.0 million for Q2 2025 and -$6.7 million for Q1 2025.